Early Lymphocyte Recovery Predicts Superior Overall Survival After Unmanipulated Haploidentical Blood and Marrow Transplantation for MDS and Acute Myeloid Leukemia Evolving From MDS  by Chang, Ying-Jun et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S200175
Immune Reconstitution Following Reduced Intensity
Stem Cell Transplantation for Non-Malignant Disorders
in Children
Jeffrey J. Bednarski II 1, Catherine Le 2, Lisa Murray 3,
Robert Hayashi 4, Lolie Yu 5, Jignesh Dalal 6, Naynesh Kamani 7,
David A. Jacobsohn 8, Michael A. Pulsipher 9,
Aleksandra Petrovic 10, Ka Wah Chan 11, Michael Grimley 12,
Paul Haut 13, Roberta Adams 14, Dorothea Douglas 15,
Sonali Chaudhury 16, Andrew Gilman 17, Jennifer Jaroscak 18,
Martin Andreansky 19, Kirk R. Schultz 20, Jennifer R Willert 21,
Shalini Shenoy 22. 1Washington University School of Medicine,
St. Louis, MO; 2Washington University School of Medicine, St.
Louis, MO; 3 Pediatric Hematology/ Oncology, Washington
University, St. Louis, MO; 4Dept of Pediatrics, St. Louis
Children's Hospital, St. Louis, MO; 5 Pediatric Hematology-
Oncology, Children's Hospital/LSUHSC New Orleans,
NewOrleans, LA; 6 BMT, Children's Mercy Hospital, Kansas City,
MO; 7 Children's National Medical Center, Washington, DC;
8 Division of Stem Cell Transplantation, Children's National
Medical Center, Washington, DC; 9 Division of Hematology and
Hematologic Malignancies, Primary Children's Medical Center/
Huntsman Cancer Institute, University of Utah School of
Medicine, Salt Lake City, UT; 10 All Children's Hospital, St.
Petersburg, FL; 11 Pediatric Blood and Marrow Stem Cell
Transplant, Texas Transplant Institute, San Antonio, TX; 12 Texas
Transplant Institute, San Antonio, TX; 13 Pediatric Hematology/
Oncology, Riley Hospital for Children/Indiana University,
Indianapolis, IN; 14 BMT Internal Medicine, Mayo Hospital,
Phoenix, AZ; 15 BMT, Phoenix Childrens Hospital, Phoenix, AZ;
16Hematology/Oncology/Stem Cell Transplantation,
Hematology/Oncology/Stem Cell Transplantation, Chicago, IL;
17 Levine's Children Hospital, Charlotte, NC; 18 UNC-CHapel Hill,
Durham, NC, United States of America; 19 University of Miami
Miller School of Medicine, Miami, FL; 20 Pediatric Hematology/
Oncology/BMT, BC Children's Hospital/UBC, Vancouver, BC,
Canada; 21 Children's Hosp San Diego, San Diego, CA;
22Washington University in St. Louis, St. Louis, MOIntroduction: Myeloablative stem cell transplants (SCT) for
nonmalignant disorders (NMD) are complicated by early and
late treatment-related toxicities. We used a novel reduced
intensity conditioning (RIC) regimen with early administra-
tion of alemtuzumab to achieve donor engraftment with
lower toxicities in NMD. Delayed immune reconstitution (IR)
and severe/fatal late infections have been previously
described with RIC using alemtuzumab peri-SCT. Early
administration in our protocol is designed to selectively
deplete host immunity with minimal effects on post-trans-
plant IR.We report the kinetics of IR and infection patterns in
the ﬁrst year post-SCT with this approach.
Methods: HSCT was performed for marrow failure, genetic
diseases or immune disorders with alemtuzumab (day -22
to -19; 33 mg if < 10 kg; 48 mg if > 10 kg), ﬂudarabine (day
-8 to -4; 150 mg/m2), and melphalan (day -3; 140 mg/m2)
followed by infusion of matched related (MRD) or matched
unrelated (MUD) marrow/PBSC. GVHD prophylaxis included
a calcineurin inhibitor (6-9 m), short course methotrexate
(days 1, 3 and 6) and short course prednisone (28 d). Stable
engraftment (> 20% donor) occurred in 89% of patients.
Lymphocyte numbers, proliferation, and immunoglobulin
levels were measured at 3, 6 and 12 m. We evaluated 35
MRD and 31 MUD recipients with immune studies collected
at a minimum of two time periods after SCT and tracked
cumulative incidence of bacterial, viral and fungal
infections.
Results: Lymphocyte, NK, CD4 and CD8 T cell numbers and
immunoglobulin levels normalized by 6 months post SCT in
both groups. MUD SCT resulted in slower IR than MRD.
Notably, MUD recipients had lower B cells after 6 months
though immunoglobulin levels were normal. The kinetics of
recovery of immune function correlated with incidence of
infections, which were highest until day 100 and declined
after day 180.
Conclusions: SCT following RIC with early administration of
alemtuzumab resulted in successful donor marrow
engraftment and rapid IR within 6 months in contrast to
previous experience. Only B cell recovery was noted to be
slower in MUD compared to MRD transplants. This RIC
regimen supports early immune recovery with reduced
and more localized infectious complications after the ﬁrst
6 months. These results provide a context for reﬁning
infection surveillance, antibiotic prophylaxis, revaccination
and return to normal lifestyle devoid of infectious
complications.176
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Early lymphocyte recovery has shown to be associated
with superior survival in patients with hematological
malignancies following umanipulated haploidentical blood
and marrow transplantion (HBMT), but its effect on clinical
outcomes in patients with myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML) evolving from MDS is
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lymphocyte recovery and transplant outcomes in 78 paients
with MDS and AML evolving from MDS receiving T-cell-
repleted transplantation from an haploidentical related
donors. The median patient follow-up was 510 days (range,
15-3419 days). Higher relapse rate was observed in patients
with an day 30 absolute lymphocyte count (ALC-30) < 300
cells/mL compared to patients with an ALC-30  300 cells/mL
(35.5% vs. 13.8%, P¼0.049). More patients had bacteria
infections in those with an ALC-30 < 300 cells/mL compared
with patients with an ALC-30  300 cells/mL (25.8% vs. 3.4%,
P¼0.015). In multivariate analysis, patients with a higher
the ALC-30 (300 cells/mL) had improved overall survival (HR
0.099, 95% CI 0.029-0.337; P<0.0001), leukemia free
survival (HR 0.271, 95% CI 0.122-0.602; P<0.0001), less
relapse (HR 0.096 95% CI 0.011-0.827; P¼0.033), and less
transplant-related mortality (TRM, HR¼0.073; 95% CI 0.016-
0.324; P¼0.001). A three human leukocyte antigen loci
mismatch was associated with a higher incidence of TRM
(HR 5.026 95% CI 1.392-18.173; P¼0.014). Our results
suggest that a higher ALC-30 ( 300 cells/mL) could be
a useful and simple tool to predict MDS and AML evolving
from MDS patients with a superior outcome after unma-
nipulated HBMT.Immune reconstitution studies following early alemtuzumab-based RIC HSCT
IR evaluated in 66 patients with data for
 2 time points
3 months 6 months 12 months
MRD MUD MRD MUD MRD MUD
ALC (cells/cumm) 1044 593* 1488 1011@ 2338 1695
CD3 (cells/cumm) 478 195
ˇ
1250 1016 1306 1116
CD4 (cells/cumm) 169 69# 565 605 770 649
CD8 (cells/cumm) 278 123# 495 386 565 440
CD16+56 (cells/cumm) 183 166 180 181 216 102
CD19 (cells/cumm) 381 37$ 498 50$ 739 175$
IgA (mg/dL) 49 35 58 34 73 44+
IgM (mg/dL) 41 25 61 59 66 47
PHA (% normal) 18% 33.9% 42.9% 44.6% 80.5% 95.0%
Infections (total
number
in all 106 patients)
Bacterial 132 69 45
Viral 106 51 37
Fungal 15 10 14
Time 3 months 3 months 6 months
Lymphocyte numbers, immunoglobulin levels and PHA proliferation are reported as median values. Infections are reported as total number of occurrences for all
patients during that time period and include both localized and systemic episodes.
@ P ¼ .03.
+ P ¼ .02.
ˇ
P ¼ .005.
* P ¼ .001.
# P ¼ .01.
$ P  .0001.177
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Cord blood transplant (CBT) recipients are at increased
risk of transplant related mortality, in part due to delayedhematopoietic and immune system recovery resulting in
increased infectious complications. However, without direct
clinical measures of immunocompetence, the speciﬁc role of
delayed immunity on CBT outcomes is not easily determined
and intervention studies not possible.
Blood samples were collected (pre-transplant and at days
28, 56, 100, 180 and 365 post-transplant) in 34 consecutive
patients undergoing myeloablative CBT for treatment of
hematologic malignancies. All samples were subjected to
Immunoseq, a novel T cell receptor (TCR) sequencing assay
that delivers an unprecedented depth of sequencing data.
From these data, clonal expansion and contraction of
hundreds of thousands of clones were tracked over time and
TCR diversity was directly measured. Basic clinical outcomes
for all patients were also determined, including GvHD,
overall survival, disease free survival, regimen related
toxicities and infectious complications.
The ability to track clones demonstrated tremendous
oscillation, with an almost entirely new T cell repertoire
appearing at least monthly in CBT recipients. Furthermore, in
contrast to healthy controls whose blood was sampled on
a similar time-course, where themost frequent Tcell clone at
one time point remains the top clone at subsequent timepoints, the largest clones observed early post-transplant in
CBT recipients subsequently dropped below detectionwithin
weeks of direct measurement. Of the 34 patients studied, six
died of infectious complications between day 100 and one
year. Notably, TCR diversity values for these six patients were
far lower than those of the remaining patients (P-value ¼
0.015, see Figure 1).
The TCR repertoire is exceptionally dynamic following
CBT, with many T cell clones rising to high frequency and
then receding to an undetectably low level in a matter of
weeks. By two months after transplant, TCR diversity accu-
rately predicted risk of death due to infection in this patient
cohort, suggesting that diversity of the TCR is a direct
measure of immunocompetence and may be useful as a test
